WO2025169153 - MAKING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE AND BUFOTENIN
National phase entry is expected:
Publication Number
WO/2025/169153
Publication Date
14.08.2025
International Application No.
PCT/IB2025/051339
International Filing Date
07.02.2025
Title **
[English]
MAKING 5-METHOXY-N,N-DIMETHYLTRYPTAMINE AND BUFOTENIN
[French]
FABRICATION DE 5-MÉTHOXY-N, N-DIMÉTHYLTRYPTAMINE ET DE BUFOTÉNINE
Applicants **
HUXLEY HEALTH, INC.
Inventors
HOMON, Anton
LARAMIE, Jaxon
HAYWARD, John
TRANT, John
Priority Data
63/550,907
07.02.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1984 | |
| EPO | Filing, Examination, Granting | 11624 | |
| Japan | Filing, Examination, Granting | 2046 | |
| South Korea | Filing, Examination, Granting | 1854 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,248
Contact Us
Abstract[English]
Disclosed is a process for, starting from melatonin, the synthesis of 2-(5-methoxy-lH-indol-3-yl)-N,Ndimethylethan-l-amine (MeO-DMT) or a bufotenin salt, said process involving nucleophilic de-acetylation, contacting the resulting 2-(5-methoxy-lH-indol-3-yl)ethan-l-amine with an aryloxy or alkoxy-carbonylation reagent to form a first carbamate, reducing the carbamate, adding a second aryloxy or alkoxy carbonylation reagent to form a second carbamate and reducing said second carbamate to form MeO-DMT followed by the addition of boron tribromide to MeO-DMT in dichloromethane to form bufotenin hydrobromide.[French]
Procédé de synthèse de 2-(5-méthoxy-1H-indol-3-yl)-N,N diméthyléthane-1-amine (MeO-DMT) ou d'un sel de bufoténine à partir de mélatonine, ledit procédé impliquant une désacétylation nucléophile, la mise en contact de 2-(5-méthoxy-1H-indol-3-yl)-éthane-1-amine résultante avec un réactif d'aryloxy- ou d'alcoxy-carbonylation pour former un premier carbamate, la réduction du carbamate, l'ajout d'un deuxième réactif d'aryloxy- ou d'alcoxy-carbonylation pour former un deuxième carbamate et la réduction dudit deuxième carbamate pour former du MeO-DMT, puis l'ajout de tribromure de bore au MeO-DMT dans du dichlorométhane pour former du bromhydrate de bufoténine.